Orlistat vs Wegovy: Which Is Right for You?

Orlistat vs Wegovy are two very different weight management medicines available in the UK, and choosing between them depends on far more than which produces greater weight loss. Orlistat is a gut-acting lipase inhibitor taken with meals, while Wegovy is a once-weekly injectable GLP-1 receptor agonist that works on the brain and pancreas. Both require lifestyle changes to be effective, and both have distinct eligibility criteria, side effect profiles and costs. This article compares the two treatments across the key areas you need to understand before speaking with a clinician.

How do orlistat and Wegovy actually work differently?

Orlistat blocks gut lipase enzymes to prevent around 30% of dietary fat being absorbed, while Wegovy (semaglutide) mimics GLP-1 to reduce appetite and slow gastric emptying by acting on the brain and pancreas.

Orlistat and Wegovy work through entirely different mechanisms: orlistat acts in the gut to block fat absorption, while Wegovy acts on the brain and pancreas to reduce appetite and regulate blood sugar. Orlistat is a lipase inhibitor, meaning it blocks the enzyme that breaks down dietary fat in the intestine. Approximately 30% of the fat consumed in a meal passes through the gut undigested and is excreted in the stool rather than being absorbed into the bloodstream, as described in the Xenical (orlistat 120 mg) SmPC. It has no effect on appetite or hormones.

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone naturally released after eating; semaglutide mimics its action by binding to GLP-1 receptors in the brain, stomach and pancreas. This slows gastric emptying, reduces appetite and promotes a feeling of fullness, leading to a lower overall calorie intake. Because it works centrally on hunger signalling, its effects extend well beyond the digestive tract.

Orlistat is taken as a capsule with each main meal containing fat, up to three times daily. Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled FlexTouch pen.^[6][7] The FlexTouch is a dial-a-dose, multi-dose pen; each pen contains multiple doses. The dose is gradually increased over several months to the maintenance level. The two medicines are therefore very different in their route of administration, their pharmacology and the lifestyle adjustments they require. Understanding these differences is important when discussing options with a clinician, as the right choice depends on individual health circumstances, preferences and tolerability.

Which one helps you lose more weight in the long run?

Wegovy produces substantially greater weight loss than orlistat; the STEP 1 trial showed approximately 14.9% mean body weight reduction with semaglutide 2.4 mg weekly, compared with 3% to 5% typically seen with orlistat.

Clinical trial evidence consistently shows that Wegovy produces substantially greater weight loss than orlistat over the long term. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), adults with obesity treated with semaglutide 2.4 mg weekly achieved a mean body weight reduction of approximately 14.9% over 68 weeks, compared with around 2.4% in the placebo group. These figures relate specifically to the 2.4 mg weekly dose studied in STEP 1. The MHRA has since authorised additional dose strengths of Wegovy up to 7.2 mg weekly; emerging evidence from the STEP UP programme suggests higher doses may offer further weight reduction, though this evidence continues to develop and should be discussed with a clinician. Orlistat trials have generally demonstrated mean weight loss in the range of 3% to 5% of body weight compared with placebo over one to two years, as summarised in NICE guidance and NHS clinical resources.^[4][5]

It is important to note that both medicines require sustained lifestyle changes, including a reduced-calorie diet and increased physical activity, to achieve and maintain results. Weight regain is common after stopping either treatment. Under current NICE guidance for NHS use, Wegovy is recommended for a defined maximum treatment period within specialist services; patients should discuss the expected duration of treatment with their clinician or specialist team, as this may differ from long-term private use. Neither medicine is a permanent solution on its own.

Orlistat remains a useful option for people who cannot tolerate injectable medicines or for whom GLP-1 receptor agonists are not appropriate. The choice between them should always be guided by a clinician who can weigh up individual health history, comorbidities and treatment goals rather than weight loss figures alone.

Who is each treatment suitable for on the NHS?

NHS orlistat is available from BMI 28 kg/m² with risk factors; NICE (TA875) recommends NHS Wegovy from BMI 35 kg/m², or 30 kg/m² in higher-risk groups, within specialist weight management services.

NHS eligibility for orlistat and Wegovy differs, and a GP or specialist is the right person to assess which treatment, if any, is appropriate for an individual. Orlistat is available on NHS prescription for adults with a body mass index (BMI) of 28 kg/m² or above with weight-related risk factors, or a BMI of 30 kg/m² or above without additional risk factors, in conjunction with a supervised weight management programme, as set out in NICE clinical guidance.^[15][16] If adequate weight loss (typically at least 5% of initial body weight) is not achieved after 12 weeks at the full prescription dose of 120 mg three times daily, treatment is usually discontinued; a clinician can advise on this.^[15][16]

Wegovy (semaglutide) is recommended by NICE (TA875) for use within specialist weight management services for adults with a BMI of at least 35 kg/m², or 30 kg/m² in certain higher-risk groups, alongside a reduced-calorie diet and increased physical activity. NICE guidance specifies that Wegovy should be used as part of a multidisciplinary tier 3 or equivalent service, and local Integrated Care Boards (ICBs) make commissioning decisions about which services are funded in their area, so availability can vary across England. Scotland, Wales and Northern Ireland have their own appraisal processes. NICE also specifies a maximum treatment duration for NHS use; patients should confirm the expected length of treatment with their specialist team.

Orlistat is generally not suitable for people with chronic malabsorption syndrome or cholestasis. Wegovy is contraindicated in those with a known hypersensitivity to semaglutide or any excipient. Neither medicine is recommended during pregnancy or breastfeeding; women who are pregnant, planning a pregnancy or breastfeeding should discuss this with their doctor before starting or continuing either treatment.

For people with type 2 diabetes who are also taking insulin or a sulfonylurea, starting a GLP-1 receptor agonist such as Wegovy may increase the risk of hypoglycaemia. A clinician should review diabetes medicines before treatment begins. People with thyroid conditions, a history of pancreatitis or other relevant comorbidities should also discuss these with their doctor before starting either medicine.

For those exploring private weight management consultations, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering prescriber-led consultations, where a clinician may consider a range of treatment options if clinically appropriate.

What side effects should you watch out for with each medicine?

Orlistat commonly causes oily stools and urgent bowel movements; Wegovy commonly causes nausea and vomiting, with rare serious risks including acute pancreatitis and gallbladder disease requiring urgent medical review.

The side effect profiles of orlistat and Wegovy are quite distinct, reflecting their different mechanisms of action. Orlistat's most common adverse effects are gastrointestinal and are directly related to unabsorbed fat passing through the bowel. These include:

• Oily or fatty stools

• Frequent or urgent bowel movements

• Faecal incontinence or spotting

• Flatulence with oily discharge

• Abdominal discomfort

These effects are more pronounced if a high-fat meal is eaten and often serve as a practical deterrent to dietary indiscretion. Orlistat can also reduce the absorption of fat-soluble vitamins (A, D, E and K), so a multivitamin taken at bedtime is often recommended.^[4][5] Rare cases of severe liver injury have been reported with orlistat; anyone who develops symptoms such as jaundice or dark urine should contact their GP promptly.^[17][3]

Orlistat has clinically relevant interactions with some other medicines. It can reduce the absorption of ciclosporin (the two should be taken at least three hours apart and ciclosporin levels monitored).^[18][19] It may affect the absorption of vitamin K and thereby alter the anticoagulant effect of warfarin, so INR should be monitored more closely in people taking warfarin. Levothyroxine absorption may also be reduced; if both are taken, they should be separated by several hours and thyroid function monitored. Anyone taking other regular medicines should ask their pharmacist or GP to check for interactions before starting orlistat.

Wegovy's most common side effects are also gastrointestinal but arise from slowed gastric emptying and central appetite suppression:

• Nausea (particularly during dose escalation)

• Vomiting

• Diarrhoea or constipation

• Abdominal pain

• Burping or reflux

Acute pancreatitis has been reported with semaglutide, including post-marketing reports of necrotising pancreatitis and cases with a fatal outcome, as noted in the Wegovy SmPC.^[20][6] Patients should seek urgent medical review if they develop severe, persistent abdominal pain; if symptoms are severe or accompanied by fever, call 999 or attend an emergency department rather than waiting for a GP appointment. GLP-1 receptor agonists are also associated with gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). Symptoms such as persistent upper abdominal pain, pain spreading to the shoulder, or yellowing of the skin or eyes should prompt urgent medical assessment.

For people with type 2 diabetes who are also taking insulin or a sulfonylurea, Wegovy may increase the risk of hypoglycaemia. Dose adjustments to diabetes medicines may be needed; this should be discussed with a clinician before starting treatment.

People with pre-existing or pre-proliferative diabetic eye disease should be aware that rapid improvements in blood glucose control may be associated with transient worsening of diabetic retinopathy, and this should be discussed with a clinician before starting treatment.

Suspected side effects from either medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

How much do orlistat and Wegovy cost in the UK?

NHS patients pay the standard prescription charge for both medicines if not exempt; private Wegovy costs significantly more and varies by dose, while orlistat 60 mg is also available over the counter as Alli.

The cost of orlistat and Wegovy in the UK varies considerably depending on whether treatment is accessed through the NHS or privately. Orlistat is available on NHS prescription, meaning eligible patients in England pay the standard NHS prescription charge per item, or nothing if they hold an exemption. Current prescription charge and prepayment certificate (PPC) fees are published by the NHS Business Services Authority (NHSBSA) and are updated periodically; the NHSBSA website is the most reliable source for up-to-date figures. A PPC covers unlimited NHS prescriptions for a fixed period and can represent a significant saving for those on multiple regular medicines.

Wegovy, when prescribed through an NHS specialist weight management service, is also subject to the standard NHS prescription charge for those who are not exempt. However, NHS access depends on local ICB commissioning decisions and referral into an appropriate service, which means not everyone who meets the NICE criteria will have immediate access through the NHS in their area.

For those accessing treatment privately, the cost of Wegovy is substantially higher and varies by dose strength and the provider used. Private consultation fees are separate from the cost of the medicine itself, and no private price should be confused with an NHS charge. Orlistat is also available over the counter at a lower dose (60 mg capsules, compared with the 120 mg prescription strength) under the brand name Alli, at a cost set by the retailer.

Anyone considering private treatment should ensure their provider is registered with the relevant regulator. Pharmacies in Great Britain should be registered with the General Pharmaceutical Council (GPhC); pharmacies in Northern Ireland should be registered with the Pharmaceutical Society of Northern Ireland (PSNI). Prescribers should be verifiable on the General Medical Council register at gmc-uk.org. Comparing costs carefully and confirming clinical oversight is in place before committing to any private weight management programme is strongly advisable.

Scientific References

1. Xenical 120mg Hard Capsules – Patient Information Leaflet / SmPC.
2. Xenical (orlistat) – EPAR Scientific Discussion.
3. Xenical (orlistat) – EPAR Product Information.
4. Orlistat | Drugs – BNF / NICE.
5. Orlistat: a medicine to treat obesity.
6. Wegovy 2.4 mg FlexTouch – Summary of Product Characteristics.
7. Wegovy 7.2 mg FlexTouch – Summary of Product Characteristics.
8. Wegovy (semaglutide) – EPAR Product Information.
9. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
10. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
11. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) – Wilding JPH et al..
12. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) – PubMed record.
13. Semaglutide for managing overweight and obesity (TA875) – Overview.
14. Semaglutide for managing overweight and obesity (TA875) – Chapter 1: Recommendations.
15. Overweight and obesity management – A guide for prescribing medicines (NG246 resource).
16. A guide for prescribing medicines to manage overweight and obesity (TA1026 resource).
17. European Medicines Agency starts review of orlistat-containing medicines.
18. Orlistat safety update.
19. Neoral Oral Solution – Summary of Product Characteristics.
20. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
21. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases – He L et al..
22. Cohort Study: Risk of Gallstones and Biliary Complications With GLP-1 Receptor Agonists in Type 2 Diabetes. United European Gastroenterology Journal..
23. Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review. International Journal of Retina and Vitreous..
24. New generation agents for glycemic control and diabetic retinopathy progression: what we need to know? Acta Diabetologica..

Frequently Asked Questions